Business
908 Devices Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Revenue Outlook
Fourth quarter 2025 revenue increased 21% compared to prior year Achieved positive Adjusted EBITDA in the fourth quarter BURLINGTON, Mass.--(BUSINESS WIRE)--
About this update from 908 Devices Inc.
[{"type":"text","content":"\nFourth quarter 2025 revenue increased 21% compared to prior year\n\n\nAchieved positive Adjusted EBITDA in the fourth quarter\n\n\n BURLINGTON, Mass.--(BUSINESS WIRE)--\n908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter and full year ended December 31, 2025.\n\n\nQ4 2025 and Full Year 2025 Financial Highlights\n\n\n\nRevenue of $17.4 million for the fourth quarter 2025, increasing 21% compared to the fourth quarter 2024\n\n\n\nRevenue of $56.2 million for the full year 2025, increasing 18% compared to the full year 2024\n\n\n\nRecurring revenue was $19.5 million for the full year 2025, increasing 22% year over year, and representing 35% of total revenues for the year\n\n\n\nGross margin was 53% and Adjusted gross margin was 57% in the fourth quarter of 2025, a 530-basis point improvement in Adjusted gross margin compared to the fourth quarter of 2024\n\n\n\nDelivered net income from continuing operations of $4.4 million and positive Adjusted EBITDA of $0.7 million for the fourth quarter 2025, achieving our goal and cash flow positivity in the fourth quarter\n\n\n\nEnded the year with a strong balance sheet, maintaining a cash position of $113.0 million\n\n\n\n“2025 was a defining year for 908 Devices as we strengthened our operating model, expanded margins, and achieved Adjusted EBITDA positivity in the fourth quarter. Our disciplined execution led to strong growth as we achieved revenue of $56.2 million in 2025, an 18% increase year over year,” said Kevin J. Knopp, CEO and Co-founder. “The structural changes we have implemented combined with a solid balance sheet give us financial flexibility to focus resources on the growing demand across the vital health, safety, and defense-tech markets we serve.”\n\n\nFourth Quarter 2025 Financial Results\n\n\nIn light of the divestiture of the bioprocessing product portfolio in March 2025, all financial results discussed in this release for current and prior periods are for continuing operations only.\n\n\nRevenue was $17.4 million for the three months ended December 31, 2025, a 21% increase over the prior year period, largely driven by an increase in FTIR product revenue. OEM and funded partnership revenue was $...